BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class Apelin Receptor Agonist BGE-105/Azelaprag Co-Administered With Tirzepatide for Treatment of Obesity, in Collaboration With Lilly’s Chorus Organization
As part of the collaboration, Lilly will also provide BioAge with tirzepatide.
- As part of the collaboration, Lilly will also provide BioAge with tirzepatide.
- “We are thrilled to work directly with the clinical development experts at Chorus and benefit from Lilly’s expertise in obesity drug development,” said Kristen Fortney, PhD, CEO and co-founder of BioAge.
- “Our Phase 2 trial is designed to assess whether azelaprag can substantially increase the weight loss achieved with drugs of the incretin class.
- Apelin signaling has demonstrated multiple benefits in energy metabolism in mouse models, including increased insulin sensitivity and reduction in fat mass.